Skip to main content

Table 1 Baseline characteristics of the patients

From: Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: a retrospective observational study

Characteristic Number of patients (%) n = 91
Gender  
Female 78 (85.7%)
Male 13 (14.3%)
Range of age  
0–20 2 (2.2%)
21–30 14 (15.4%)
31–40 27 (29.7%)
41–65 48 (52.7%)
Ethnicity  
Middle East 45 (49.4%)
Asian 17 (18.7%)
Europe 20 (22.0%)
Rest of the world 9 (9.9%)
Previous years of migraine  
0–19 years 31 (34.1%)
≥20 years 60 (65.9%)
Type of migraine  
Medication overuse headache 14 (15.4%)
Episodic migraine 33 (36.3%)
Chronic migraine 44 (48.3%)
Reduction of migraine days in all migraine types  
0–24% 13 (14.3%)
25–49% 5 (5.5%)
50–74% 10 (11.0%)
75–100% 63 (69.2%)
Dose increase of erenumab to 140 mg  
Yes 14 (15.4%)
No 77 (84.6%)